- Home
- BNR vs INKT Comparison
BNR vs INKT Comparison
Compare BNR & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNR
- INKT
- Stock Information
- Founded
- BNR 2014
- INKT 2017
- Country
- BNR China
- INKT United States
- Employees
- BNR N/A
- INKT N/A
- Industry
- BNR Medical Specialities
- INKT Medicinal Chemicals and Botanical Products
- Sector
- BNR Health Care
- INKT Health Care
- Exchange
- BNR Nasdaq
- INKT Nasdaq
- Market Cap
- BNR 38.3M
- INKT 28.8M
- IPO Year
- BNR 2020
- INKT 2021
- Fundamental
- Price
- BNR $4.87
- INKT $41.04
- Analyst Decision
- BNR
- INKT Strong Buy
- Analyst Count
- BNR 0
- INKT 2
- Target Price
- BNR N/A
- INKT $37.50
- AVG Volume (30 Days)
- BNR 29.7K
- INKT 2.4M
- Earning Date
- BNR 08-21-2025
- INKT 08-12-2025
- Dividend Yield
- BNR N/A
- INKT N/A
- EPS Growth
- BNR N/A
- INKT N/A
- EPS
- BNR N/A
- INKT N/A
- Revenue
- BNR $72,112,038.00
- INKT N/A
- Revenue This Year
- BNR $136.32
- INKT N/A
- Revenue Next Year
- BNR N/A
- INKT N/A
- P/E Ratio
- BNR N/A
- INKT N/A
- Revenue Growth
- BNR 0.53
- INKT N/A
- 52 Week Low
- BNR $2.18
- INKT $4.56
- 52 Week High
- BNR $7.90
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- BNR 63.77
- INKT 69.01
- Support Level
- BNR $3.06
- INKT $6.80
- Resistance Level
- BNR $3.50
- INKT $76.00
- Average True Range (ATR)
- BNR 0.21
- INKT 4.65
- MACD
- BNR 0.05
- INKT 4.24
- Stochastic Oscillator
- BNR 95.65
- INKT 49.48
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.